Abstract

Conduct Phase I and Clinical Pharmacokinetic studies on specific investigational new drugs sponsored by the Division of Cancer Treatment (DCT), National Cancer Institute (NCI). The Contractor shall provide the parameters and characteristics of drug toxicity, the maximally tolerated dose, and recommend a phase II dose.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM057737-009
Application #
3613326
Study Section
Project Start
1985-08-01
Project End
1990-04-30
Budget Start
1990-03-01
Budget End
1990-04-30
Support Year
Fiscal Year
1990
Total Cost
Indirect Cost

  Institution

Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229

  Publications

Marshall, M V; Carey, K D; Von Hoff, D D et al. (1995) Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons. Invest New Drugs 13:33-6
Marshall, M V; Marshall, M H; Degen, D R et al. (1993) In vitro cytotoxicity of hepsulfam against human tumor cell lines and primary human tumor colony forming units. Stem Cells 11:62-9
Havlin, K A; Kuhn, J G; Craig, J B et al. (1991) Phase I clinical and pharmacokinetic trial of flavone acetic acid. J Natl Cancer Inst 83:124-8
Von Hoff, D D; Turner, J (1991) Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9:115-22
Phillips, J L; Schwartz, R; Von Hoff, D D (1989) In vitro distribution of diacetyl didemnin B in human blood cells and plasma. Cancer Invest 7:123-8
Friess, G G; Brown, T D; Wrenn, R C (1989) Cardiovascular rhythm effects of gamma recombinant DNA interferon. Invest New Drugs 7:275-80
Scheithauer, W; Moyer, M P; Clark, G M et al. (1988) Application of a new preclinical drug screening system for cancer of the large bowel. Cancer Chemother Pharmacol 21:31-4
Merkel, D E; Griffin, N L; Kagan-Hallet, K et al. (1986) Central nervous system toxicity with fludarabine. Cancer Treat Rep 70:1449-50
Scheithauer, W; Clark, G M; Salmon, S E et al. (1986) Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep 70:1379-82